GT Biopharma (GTBP) Stock Price, News & Analysis

Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Key Stats

• Today's Range: $2.97 to $3.19
• 50-Day Range: $1.97 to $3.47
• 52-Week Range: $1.92 to $10.66
• Volume: 5,753 shs
• Average Volume: 398,531 shs
• Market Capitalization: $6.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GTBP Stock Analysis - Frequently Asked Questions

How have GTBP shares performed this year?

GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP stock has decreased by 60.7% and is now trading at $3.01.
View the best growth stocks for 2024 here.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Thursday, April, 15th. The company reported ($101.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $100.50.

When did GT Biopharma's stock split?

GT Biopharma's stock reverse split on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are GT Biopharma's major shareholders?

Top institutional investors of GT Biopharma include DekaBank Deutsche Girozentrale. Insiders that own company stock include Michael Martin Breen and Manu Ohri.
View institutional ownership trends.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

• Last Earnings: 4/15/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GTBP
• Previous Symbol: OTCMKTS:OXISD
• CUSIP: N/A
• CIK: 109657
• Web: www.gtbiopharma.com
• Phone: (415) 919-4040
• Fax: N/A
• Employees: 8
• Year Founded: 1965

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,600,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -257.47%
• Return on Assets: -131.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.45
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 3.20

Miscellaneous

• Outstanding Shares: 2,230,000
• Free Float: 1,990,000
• Market Cap: $6.71 million
• Optionable: No Data
• Beta: 0.57